TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Dey, Nirmalya ^a   Ghosh Choudhury, Nandini ^a,b   Kasinath, Balakuntalam S ^a,b   Choudhury, Goutam Ghosh ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROLINE RICH PROTEIN; PROTEIN KINASE B; PROTEIN MTORC1; PROTEIN PRAS40; S6 KINASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUBERIN; UNCLASSIFIED DRUG;

ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; HYPERTROPHY; MESANGIAL CELLS; MICRORNAS; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 84864541155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042316     Document Type: Article

References (102)

1. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC, (2003) TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 284: F243-252.
2. Eddy AA, Neilson EG, (2006) Chronic kidney disease progression. J Am Soc Nephrol 17: 2964-2966.
3. Bottinger EP, (2007) TGF-beta in renal injury and disease. Semin Nephrol 27: 309-320.
4. Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, et al. (1996) Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 49: 1120-1126.
5. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, et al. (1996) Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74: 991-1003.
6. Border WA, Noble NA, (1998) Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 54: 1390-1391.
7. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020.
8. Attisano L, Wrana JL, (2002) Signal transduction by the TGF-beta superfamily. Science 296: 1646-1647.
9. Shi Y, Massague J, (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
10. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL, (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95: 779-791.
11. Izzi L, Attisano L, (2004) Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 23: 2071-2078.
12. Xu L, Chen YG, Massague J, (2000) The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol 2: 559-562.
13. Lan HY, (2011) Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 7: 1056-1067.
14. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, et al. (2003) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305: 1002-1007.
15. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A, (2003) Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486-1494.
16. Zhou L, Fu P, Huang XR, Liu F, Chung AC, et al. (2010) Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 298: F1006-1017.
17. Meng XM, Huang XR, Chung AC, Qin W, Shao X, et al. (2010) Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 21: 1477-1487.
18. Moustakas A, Heldin CH, (2009) The regulation of TGFbeta signal transduction. Development 136: 3699-3714.
19. Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ, (2005) Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. J Cell Physiol 204: 236-246.
20. Samarakoon R, Higgins SP, Higgins CE, Higgins PJ, (2008) TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 44: 527-538.
21. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL, (2000) Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275: 36803-36810.
22. Ghosh Choudhury G, Abboud HE, (2004) Tyrosine phosphorylation-dependent PI 3 kinase/Akt signal transduction regulates TGFbeta-induced fibronectin expression in mesangial cells. Cell Signal 16: 31-41.
23. Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliers D, et al. (2008) Raptor-rictor axis in TGFbeta-induced protein synthesis. Cell Signal 20: 409-423.
24. Lamouille S, Derynck R, (2007) Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178: 437-451.
25. Mahimainathan L, Das F, Venkatesan B, Choudhury GG, (2006) Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55: 2115-2125.
26. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
27. Fabian MR, Sonenberg N, Filipowicz W, (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
28. Lorenzen JM, Haller H, Thum T, (2011) MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7: 286-294.
29. Suzuki HI, Arase M, Matsuyama H, Choi YL, Ueno T, et al. (2011) MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol Cell 44: 424-436.
30. Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, McMahon AP, et al. (2011) Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 79: 317-330.
31. Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, et al. (2008) Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 19: 2069-2075.
32. Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, et al. (2008) Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 19: 2150-2158.
33. Shi S, Yu L, Chiu C, Sun Y, Chen J, et al. (2008) Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 19: 2159-2169.
34. Zhdanova O, Srivastava S, Di L, Li Z, Tchelebi L, et al. (2011) The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int 80: 719-730.
35. Wei Q, Bhatt K, He HZ, Mi QS, Haase VH, et al. (2010) Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 21: 756-761.
36. Ho J, Kreidberg JA, (2012) The Long and Short of MicroRNAs in the Kidney. J Am Soc Nephrol 23: 400-404.
37. Kato M, Arce L, Natarajan R, (2009) MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 4: 1255-1266.
38. Bhatt K, Zhou L, Mi QS, Huang S, She JX, et al. (2010) MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med 16: 409-416.
39. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, et al. (2011) The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U S A 108: 12030-12035.
40. Denby L, Ramdas V, McBride MW, Wang J, Robinson H, et al. (2011) miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am J Pathol 179: 661-672.
41. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY, (2011) Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 22: 1668-1681.
42. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G, (2011) Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 301: F793-801.
43. Kato M, Putta S, Wang M, Yuan H, Lanting L, et al. (2009) TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11: 881-889.
44. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K, (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39: 493-506.
45. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
46. Ebert MS, Neilson JR, Sharp PA, (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726.
47. Cantley LC, Neel BG, (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245.
48. Cully M, You H, Levine AJ, Mak TW, (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
49. Kasinath BS, Feliers D, Sataranatarajan K, Ghosh Choudhury G, Lee MJ, et al. (2009) Regulation of mRNA translation in renal physiology and disease. Am J Physiol Renal Physiol 297: F1153-1165.
50. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, et al. (2006) Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 340: 296-301.
51. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, et al. (2007) Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol 171: 1733-1742.
52. Chen JK, Chen J, Neilson EG, Harris RC, (2005) Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16: 1384-1391.
53. Huang J, Manning BD, (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412: 179-190.
54. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
55. Dey N, Ghosh-Choudhury N, Das F, Li X, Venkatesan B, et al. (2010) PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. J Cell Physiol 225: 27-41.
56. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, et al. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278: 10189-10194.
57. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
58. Chiang GG, Abraham RT, (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280: 25485-25490.
59. Hay N, Sonenberg N, (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
60. van Weering DH, de Rooij J, Marte B, Downward J, Bos JL, et al. (1998) Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. Mol Cell Biol 18: 1802-1811.
61. Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, et al. (2008) Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 283: 31861-31870.
62. Das F, Ghosh-Choudhury N, Dey N, Mandal CC, Mahimainathan L, et al. (2012) Unrestrained Mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of akt kinase. J Biol Chem 287: 3808-3822.
63. Leslie NR, Foti M, (2011) Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 32: 131-140.
64. Kato M, Zhang J, Wang M, Lanting L, Yuan H, et al. (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104: 3432-3437.
65. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, et al. (2010) E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 59: 1794-1802.
66. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, et al. (2010) Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 21: 438-447.
67. Jenkins RH, Martin J, Phillips AO, Bowen T, Fraser DJ, (2012) Transforming growth factor beta1 represses proximal tubular cell microRNA-192 expression through decreased hepatocyte nuclear factor DNA binding. Biochem J 443: 407-416.
68. Putta S, Lanting L, Sun G, Lawson G, Kato M, et al. (2012) Inhibiting MicroRNA-192 Ameliorates Renal Fibrosis in Diabetic Nephropathy. J Am Soc Nephrol 23: 458-469.
69. Kantharidis P, Wang B, Carew RM, Lan HY, (2011) Diabetes complications: the microRNA perspective. Diabetes 60: 1832-1837.
70. Badal SS, Danesh FR, (2012) Managing microvascular complications of diabetes with microRNAs. J Am Soc Nephrol 23: 185-187.
71. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, et al. (2011) TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22: 1462-1474.
72. Chau BN, Xin C, Hartner J, Ren S, Castano AP, et al. (2012) MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways. Sci Transl Med 4: 121ra118.
73. Cheng Y, Ji R, Yue J, Yang J, Liu X, et al. (2007) MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 170: 1831-1840.
74. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, et al. (2007) Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42: 1137-1141.
75. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, et al. (2010) Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18: 282-293.
76. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
77. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
78. Laplante M, Sabatini DM, (2012) mTOR signaling in growth control and disease. Cell 149: 274-293.
79. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, et al. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501.
80. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL, (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10: 935-945.
81. Wang L, Harris TE, Roth RA, Lawrence JC Jr, (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282: 20036-20044.
82. Das F, Ghosh-Choudhury N, Venkatesan B, Li X, Mahimainathan L, et al. (2008) Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J Cell Physiol 214: 513-527.
83. Runyan CE, Schnaper HW, Poncelet AC, (2004) The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem 279: 2632-2639.
84. Mariappan MM, Feliers D, Mummidi S, Choudhury GG, Kasinath BS, (2007) High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 56: 476-485.
85. Mariappan MM, Shetty M, Sataranatarajan K, Choudhury GG, Kasinath BS, (2008) Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells. J Biol Chem 283: 30566-30575.
86. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
87. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S, (2010) microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle 9: 2742-2748.
88. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, et al. (2010) MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell 37: 620-632.
89. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM, (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326: 1707-1711.
90. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, et al. (2010) Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 12: 372-379.
91. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW, (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22: 239-251.
92. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107: 264-269.
93. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, et al. (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70: 5184-5193.
94. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, et al. (2010) Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A 107: 16228-16233.
95. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, et al. (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24: 447-463.
96. Davis BN, Hilyard AC, Lagna G, Hata A, (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56-61.
97. Shultz PJ, DiCorleto PE, Silver BJ, Abboud HE, (1988) Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 255: F674-684.
98. Choudhury GG, Biswas P, Grandaliano G, Abboud HE, (1993) Involvement of PKC-alpha in PDGF-mediated mitogenic signaling in human mesangial cells. Am J Physiol 265: F634-642.
99. Choudhury GG, Biswas P, Grandaliano G, Fouqueray B, Harvey SA, et al. (1994) PDGF-mediated activation of phosphatidylinositol 3 kinase in human mesangial cells. Kidney Int 46: 37-47.
100. Choudhury GG, Ghosh-Choudhury N, Abboud HE, (1998) Association and direct activation of signal transducer and activator of transcription1alpha by platelet-derived growth factor receptor. J Clin Invest 101: 2751-2760.
101. Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, et al. (2009) Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat 118: 213-228.
102. Mahimainathan L, Ghosh-Choudhury N, Venkatesan B, Das F, Mandal CC, et al. (2009) TSC2 deficiency increases PTEN via HIF1alpha. J Biol Chem 284: 27790-27798.